Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

FLIPI (Follicular Lymphoma)

The FLIPI score is the standard tool for predicting survival in patients with follicular lymphoma.

Evidence-based context for fast calculator use

Purpose:
FLIPI predicts overall survival in follicular lymphoma using five prognostic factors to stratify patients into low, intermediate, or high risk.
Population:
patients with the specific hematologic diagnosis and disease phase described by the model
Factors:
Number of Nodal Sites Involved > 4?, Serum LDH > Upper Limit of Normal?, Age ≥ 60 years?, Ann Arbor Stage III or IV?, Hemoglobin < 120 g/L?
Reference:
Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258-1265.
HomeFLIPI (Follicular Lymphoma)
Pin your most used calculators here by clicking the star in the dropdown.

FLIPI (Follicular Lymphoma)

Clinical Context & Background

The FLIPI score is the standard tool for predicting survival in patients with follicular lymphoma. It uses five adverse prognostic factors (Acronym: NoLSH).
Primary Source EvidenceSolal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258-1265.
Formula Logic
Sum of: Nodes >4, LDH >Normal, Stage III-IV, Hb <120, Age ≥60

Reference Data

Risk GroupScore10-Year Overall Survival
Low Risk0 - 171%
Intermediate Risk251%
High Risk3 - 536%

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use FLIPI (Follicular Lymphoma) when fLIPI predicts overall survival in follicular lymphoma using five prognostic factors to stratify patients into low, intermediate, or high risk.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning Low Risk through High Risk.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm morphology, molecular/cytogenetic data, treatment timing, laboratory units, and the current disease-specific guideline before acting.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Hematology scores are diagnosis-, phase-, and treatment-specific and should not be transferred between diseases.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients with the specific hematologic diagnosis and disease phase described by the model

How to apply this result

For a representative case, verify Number of Nodal Sites Involved > 4?, Serum LDH > Upper Limit of Normal?, Age ≥ 60 years?, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Hematology hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

NCCN-IPI (Lymphoma)CLL-IPIMIPI (Mantle Cell Lymphoma)

Frequently Asked Questions

When should FLIPI (Follicular Lymphoma) be used?

Use it for patients with the specific hematologic diagnosis and disease phase described by the model when all required inputs and the intended clinical setting are confirmed.

Can FLIPI (Follicular Lymphoma) determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.